Publication Name	World Journal of Gastroenterology
Manuscript ID	2030
Country	Thailand

Received	2013-01-22 09:31
Peer-Review Started	2013-01-22 14:14
To Make the First Decision	2013-03-04 11:54
Return for Revision	2013-03-08 10:22
Revised	2013-04-19 10:57
Second Decision	2013-06-19 12:51
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-06-20 00:43
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor	2013-07-05 22:41
Typeset the Manuscript	2013-08-08 14:35
Publish the Manuscript Online	2013-08-19 18:22

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Autobiography
Article Title	Serum proteins in chronic hepatitis B patients treated with peginterferon alfa-2b
Manuscript Source	Invited Manuscript
All Author List	Sunida Kuakarn, Poorichaya SomParn, Pisit Tangkijvanich, Varocha Mahachai, Visith Thongboonkerd and Nattiya Hirankarn
Funding Agency and Grant Number	Funding Agency Grant Number 90th Anniversary of Chulalongkorn University Fund (Ratchadaphiseksomphot Endowment Fund) Thailand Research Fund RMU5180051 Thailand Research Fund Senior Research Scholarship RTA5380005 Higher Education Research Promotion and National Research University Project of Thailand, Office of the Higher Education Commission HR1163A Integrated Innovation Academic Center, Chulalongkorn University Centenary Academic Development Project CU56-HR05 Liver Research Unit, Chulalongkorn University
Corresponding Author	Nattiya Hirankarn, MD, PhD, Immunology Unit, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, 254 Phayathai Road, Pathumwan, Bangkok 10330, Thailand. nattiyap@gmail.com
Key Words	Proteomics; Peginterferon alfa-2b; Chronic hepatitis B; Alpha-2-HS-glycoprotein; Serum
Core Tip	Serum proteins serve as non-invasive biomarkers for several diseases. This is the first report on the potential use of common protein levels in the serum of chronic hepatitis B (CHB) patients to predict treatment responsiveness to peginterferon alfa-2b. We identified 2 potential serum biomarkers, alpha-2-HS-glycoprotein and complement component C3c, that can be used to predict treatment outcome in patients with CHB receiving peginterferon alfa-2b. The identification of these biomarkers prior to treatment is preferable in order to avoid systemic side effects due to interferon therapy.
Publish Date	2013-08-19 18:22
Citation	Kuakarn S, SomParn P, Tangkijvanich P, Mahachai V, Thongboonkerd V, Hirankarn N. Serum proteins in chronic hepatitis B patients treated with peginterferon alfa-2b. World J Gastroenterol 2013; 19(31): 5067-5075
URL	http://www.wjgnet.com/1007-9327/full/v19/i31/5067.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i31.5067

Full Article (PDF)	WJG-19-5067.pdf
Manuscript File	2030-Review.doc
Answering Reviewers	2030-Answering reviewers.pdf
Copyright License Agreement	2030-Copyright assignment.PDF
Institutional Review Board Approval Form or Document	EC.pdf
Non-Native Speakers of English Editing Certificate	2030-Language certificate.pdf
Peer-review Report	2030-Peer review.pdf
Scientific Editor Work List	2030-Scientific editor work list.doc